eDruginfo.com
Wolters Kluwer | Lippencott Williams & Wilkins
Drug Warnings

   Drug Updates

   Patient Teaching

   Drug Warnings

   News Capsules

   Herbal Spotlight

   Quik Tools

   Drug Info Links

   Drug Info Bookstore

   Feedback

   Registration

   Disclaimer



mycophenolate
Myfortic
  Pharmaceutical company:
Novartis
www.novartis.com

NEW WARNING
Novartis has issued a “Dear Healthcare Professional” letter to announce new warnings associated with mycophenolate (Myfortic), an immune suppressant used to prevent transplant rejection. Reports of serious congenital malformations and miscarriages that have occurred when the drug has been used during pregnancy have resulted in a change from Pregnancy Category C to Pregnancy Category D. Providers are required to counsel female patients of childbearing age to use effective contraceptives while on this drug and to advise the switch to another immune suppressant if a pregnancy is planned. The prescribing information now has a boxed warning about the risk of use during pregnancy and increased information about the related findings in the Precautions section.

     
   

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our
Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins